膜杰作
Star Staining
抗体来源（Source）
Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.
亚型（Isotype）
Human IgG1 | Human Kappa
偶联（Conjugate）
Unconjugated
抗体类型（Antibody Type）
Recombinant Monoclonal
种属反应性（Reactivity）
Virus
特异性（Specificity）
This product is a specific antibody specifically reacts with HRSV F-Palivizumab.
应用（Application）
| Application | Recommended Usage |
| ELISA | 0.3-156 ng/mL |
纯度（Purity）
>95% as determined by SDS-PAGE.
纯化（Purification）
Protein A purified/ Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
活性（Bioactivity）-ELISA
Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) (Cat. No. HRF-M789) with a linear range of 0.3-5 ng/mL (QC tested).
Protocol
Immobilized HRSV (B) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H9) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) (Cat. No. HRF-M789) with a linear range of 0.3-5 ng/mL (QC tested).
Protocol
Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) (Cat. No. HRF-M789) with a linear range of 0.3-5 ng/mL (Routinely tested).
Protocol
Immobilized HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-HRSV F Antibody, Human IgG1 (Palivizumab) (Cat. No. HRF-M789) with a linear range of 0.3-5 ng/mL (Routinely tested).
Protocol
背景（Background）
Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.
Antibody Palivizumab, a humanized monoclonal antibody targeting the antigenic site II region of the RSV F protein.
